Arcellx, Inc. (ACLX)

53,62 +0,83 (+1,57%) Börsenschluss: 04:00PM EDT

Arcellx, Inc.

800 Bridge Parkway
Redwood City, CA 94065
United States
240 327 0603
https://www.arcellx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 130

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Rami Elghandour	Chairman of the Board, CEO & President	941,67k	N/A	1979
Ms. Michelle Lim Gilson	Chief Financial Officer	602,8k	N/A	1993
Dr. Christopher R. Heery M.D.	Chief Medical Officer	683,4k	N/A	1980
Mr. Narinderjeet Singh M.S.	Chief Technical Officer	N/A	N/A	1972
Mr. David Tice Ph.D.	Chief Scientific Officer	N/A	N/A	1971
Ms. Myesha Lacy	Chief Investor & Communications Officer	N/A	N/A	N/A
Ms. Maryam Abdul-Kareem J.D., M.S.	General Counsel & Chief Legal Officer	N/A	N/A	N/A
Ms. Kate Aiken	Chief People Officer	N/A	N/A	N/A
Mr. Neeraj P. Teotia	Chief Commercial Officer	461,95k	N/A	1975
Ms. Aileen Fernandes	Chief Business Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Corporate Governance

Arcellx, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 10. Die grundlegenden Scores sind Audit: 9, Vorstand: 9, Shareholderrechte: 8, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.